A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

计划入组 34 人 · 首次发布于 2009 年 6 月 29 日

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

计划入组 4 人 · 首次发布于 2011 年 10 月 27 日

Positron Emission Tomography (PET) Study to Describe the Relationship Between Plasma Concentrations and Brain Gly-T1 Occupancy of GSK1018921 Over Time.

计划入组 12 人 · 首次发布于 2009 年 7 月 24 日

Glycine(Aminosyn II 7 %, Sulfite-free, Aminosyn-PF 7%, Clinimix 2.75/5, Clinimix E 2.75/5, Clinisol 15, Freamine 6.9, Freamine III 10, Hepatamine 8, Olimel, Periolimel, Plenamine, Premasol, Primene, Procalamine 3, Prosol, Travasol 10, Trophamine 10 %)

<dd class="col-xl-8 col-md-9 col-sm-8">C₂H₅NO₂</dd>

MA-0779

oral glycine

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

Boehringer Ingelheim's Iclepertin Fails to Meet Endpoints in Phase III Schizophrenia Trials

Disc Medicine Announces End-of-Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria

Disc Medicine Gains FDA Alignment on Bitopertin Trial Design for Erythropoietic Protoporphyria